Biotech | May 01, 2022
BeiGene to open new site at Princeton, New Jersey
Flagship U.S. facility will include biologic manufacturing and late stage research and clinical development of innovative cancer medicines
Flagship U.S. facility will include biologic manufacturing and late stage research and clinical development of innovative cancer medicines
The respective expertise of Lonza and Integral Molecular will benefit drug developers in the assessment of the risk for off-target binding and activation
Under the terms of the agreement, Bachem will provide the appropriate engineering infrastructure and expertise to implement Lilly’s novel oligonucleotide manufacturing technology
The $44 million facility is part of Thermo Fisher's $650 million multi-year investment, announced last year, to help ensure flexible, scalable and reliable bioprocessing production capacity exists for critical materials used in developing new and existing biologics and vaccines, including for COVID-19
This is the first major brand refresh of CanSinoBIO since its inception in 2009
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
The Phase 3 trial will be conducted under the auspices of the first Regenerative Medicine Advanced Therapy (RMAT) designation approved by the USFDA for an EV therapeutic
Support for biologics manufacturability and Industry 4.0 initiatives
Marks the second of three biosimilars Amneal expects to receive U.S. approval for in 2022
An RMAT confers eligibility for accelerated approval and priority review of biologics licensing applications (BLA)
Subscribe To Our Newsletter & Stay Updated
